APRINOIA Therapeutics (APRI) files for a proposed IPO.
The company describes itself as: 'We are a clinical-stage biotechnology company committed to protecting patients’ brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics.'
US Tiger Securities will serve as lead underwriter.